Hirect Q2 FY27: consol PAT crashes 81% YoY to ₹2.9 Cr as EMS, Elventive losses bite
PAT -80.51% YoY · revenue +38.98% · margins compressing
₹315.69 Cr
+38.98% YoY
₹2.87 Cr
-80.51% YoY
0.91%
-5.6pp YoY
₹1.94
Hirect Limited (formerly Hind Rectifiers) posted consolidated revenue of ₹315.69 Cr for Q2 FY27, up 38.98% YoY and 22.15% QoQ, but consolidated net profit for the period fell 80.51% YoY to ₹2.87 Cr, down 55.85% QoQ from ₹6.50 Cr in Q1 FY27 and ₹14.72 Cr a year ago. A ₹2.68 Cr exceptional gain — a size consistent with the ₹4.5 Cr sale of the non-operational Dehradun plant announced September 24, 2026 — flattered the headline; stripping it out, underlying consolidated PAT was only ~₹0.19 Cr, down ~98.7% YoY on an adjusted basis, effectively a breakeven quarter at the group level.
Q2 FY-2027 vs prior quarters
The gap between the standalone core business and the consolidated group explains the weakness. Standalone revenue grew 29.59% YoY to ₹294.35 Cr — essentially on pace with management's maintained FY27 target of 30% growth — and standalone PAT of ₹14.52 Cr was roughly flat both YoY (-1.5%) and QoQ (-3.8%). But the newly consolidated EMS segment (added this year, not YoY-comparable per the filing's own note) posted a ₹(10.99) Cr segment loss this quarter, and Elventive France continues to weigh on margins exactly as management flagged on the August 2026 call. Consolidated EBITDA margin came in at an estimated ~4.3%, down from ~5.1% in Q1 FY27 and ~11.4% a year ago; standalone EBITDA margin itself slipped to ~8.2% from ~10.6% in Q1, missing management's own guided 10.6-10.8% standalone range. Non-controlling interest absorbed the EMS/Elventive losses, so profit attributable to Hirect's own shareholders was a healthier ₹6.82 Cr even as total consolidated PAT was near zero.
The stock went into the print at ₹908.95, down 18.4% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY27 30% revenue growth maintained (from ₹1,033 Cr base implies ~₹1,343 Cr target). Standalone ~10.6-10.8% EBITDA margin; consolidated margins constrained 3-5 quarters by Elventive France integration toward breakeven. Propulsion field trials completion in coming months; U.S. shipments within 6-12 months.
— This quarter: missed
No management press release accompanied this filing, and no Q2 FY27 analyst estimates or consensus previews turned up in available coverage — Hirect carries thin formal street coverage. Pre-print commentary had flagged margin stabilization as the key swing factor for the quarter; margins instead compressed further, a disappointment against that informal bar. Against management's own prior guidance the picture is mixed: the ~30% revenue growth target is roughly on track quarterly (standalone +29.59% YoY) even though cumulative H1 growth of ~20% trails the full-year pace, while the 10.6-10.8% standalone EBITDA margin guidance was missed this quarter after being met in Q1. The quarter also carried the Dehradun plant sale, a legal-head resignation, and the RTA change to Bigshare — none of which move the P&L beyond the exceptional gain already noted. This sets up H2 FY27 as the test of whether Elventive France's guided 3-5 quarter path to breakeven starts showing in the margin line, and whether the EMS segment's losses begin narrowing.
W1
Consolidated EBITDA margin recovery from ~4.3% — management guided a 3-5 quarter path to breakeven for Elventive France from the Q1 FY27 call.
W2
H2 FY27 revenue trajectory needed to hit the full-year 30% growth guidance — standalone H1 growth of ~20% trails the ~30% quarterly run-rate.
W3
EMS segment loss trend (₹(10.99) Cr this quarter) as the unit scales — next quarter will show if losses narrow.